Astrology and the interpretation of data from clinical trials

Over the weekend, an  interesting article on clinical trials appeared (somewhat unexpectedly) in the New York Times color supplement. … READ MORE …

Some thoughts on the president’s cancer “moon shot”

It has been a couple of weeks now since Vice President Biden started work on the cancer “moon shot” initiative that President Obama announced during the State of the Union speech to Congress on January 12. … READ MORE …

SBRT registries (and the interpretation of registry-based data)

Patient registries are potentially a rich source of information with which to evaluate outcomes. They often include patient characteristics, details of the therapies they received, and outcomes tracked over time. They also provide full population data of all patients treated at participating centers, and can provide very large amounts of data over time. … READ MORE …

Fallout from elimination of PSA data from the SEER database

On April 29 this year, the National Cancer Institute (NCI) announced a decision to eliminate all PSA data from their current data files because of apparent inaccuracies in the ways that such data had been accumulated over time and administered. The full ramifications of this are — as yet — unclear. … READ MORE …

US national prostate cancer registry coming to life soon

At the annual meeting of the American Urological Association (AUA) this morning, Dr. Matt Cooperberg reported that a total of 450 US-based urologists had now signed up to contribute data on their prostate cancer patients to the AQUA Registry. … READ MORE …

Payers tell PBRT centers that they need better data to justify high prices

According to media reports this morning, a number of payer organizations in the USA are initiating new policies regarding the coverage of proton beam radiation therapy (PBRT) for the treatment of localized prostate cancer. … READ MORE …

ASCO’s new CancerLinQ initiative

As we move near to the annual meeting of the American Society of Clinical Oncology (ASCO) — which will start at the end of May in Chicago — ASCO has been making a lot of noise about its prototype CancerLinQ™ network. Just how valuable this will be for the future management of prostate cancer will take a while to work out. … READ MORE …